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1. Introduction/Background 
In 2003, British Columbia (BC) opted to discontinue routine Bacille Calmette-Guerin (BCG) 
vaccination for First Nation children and replace this with enhanced tuberculosis (TB) control 
activities as recommended by First Nations and Inuit Health, Health Canada (Public Health 
Agency of Canada, National Advisory Committee Statement on BCG, 2004). BCG is the most 
widely administered vaccine in the world and is used to prevent serious forms of TB in children, 
most notably TB meningitis and miliary TB (Fine, P., Carneiro, T, Milstien, J. & Clements, C.J., 
1999). Evaluation of reports detailing serious adverse events caused by the BCG vaccine in some 
First Nation children raised concerns that the routine neonatal BCG immunization program may 
well be associated with unforeseeable and unacceptable health risks (Public Health Agency of 
Canada, 2004a). The decision to shift from mass vaccination of infants to selective vaccination 
of high risk groups is guided by criteria established by the International Union against 
Tuberculosis and Lung Disease (lUATLD) (World Health Organization, 2004). Of significant 
importance to meeting these criteria, there must be an efficient notification system in place to 
monitor, case find and treat active TB cases. 
BC Center for Disease Control (BCCDC) is the centralized health authority for maintaining 
communicable disease registry and services for the province of British Columbia. All core TB 
services are delivered by BCCDC in partnership with First Nation & Inuit Health, Pacific 
Region. To monitor and improve TB eontrol efforts with First Nation reserves, an enhanced 
surveillance and screening program was developed and implemented in June 2004. 
Effective evaluation of the enhanced surveillance program will help facilitate future direction for 
TB control initiatives and priorities with First Nation communities and provide additional 
research for public health poliey. 
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1.1 Pathophysiology of Tuberculosis 
Mycobacterium tuberculosis (Mtb), the bacteria that cause TB, have seriously plagued mankind 
for centuries. The genetically related group known as Mycobacterium TB complex (or MTBC) 
has been established as the case definition of TB in Canada, and includes the species M. bovis, 
M. africanuum, M. caprae, M. microti and M. pinnipedii (Canadian Tuberculosis Standards, 
2007). Mtb is the etiologic agent of TB in humans; therefore humans are the only reservoir for 
this bacterium. Mtb is a nonmotile rod shaped bacterium that requires oxygen, hence why classic 
cases of active TB are found in the well-aerated upper lobes of the lung (Todar, 2009). The 
unique and sophisticated cell wall deserves special attention as it contains high concentrations of 
complex fatty acid that provide an extroardinary lipid barrier. The cell wall of this bacterium has 
been associated with impermeability to stains and dyes, resistance to many antibiotics, and acidic 
and alkaline compounds (World Health Organization, 2004). Of particular significance is its 
resistance to osomotic lysis and lethal oxidations which allow it to survive inside of macrophages 
(Todar, 2009). Transmission of Mtb occurs when droplet nuclei containing Mtb bacilli are 
expelled by coughing, sneezing, singing or other forceful expectoration. These droplets can 
remain suspended in the air for minutes to hours depending on ventilation factors. The number of 
bacilli in the droplets, the virulence of the bacterium, exposure of the bacilli to UV light, the 
degree of ventilation in a room, and your own immune system, all influence the risk of 
transmission (Knechel, 2009). Infection by Mtb and the clinical manisfestations that may ensue 
also represent a complex interaction between host and organism (Schluger, 2005). Once the 
infectious droplets have been inhaled, the Mtb must gain entry to the alveoli of the lung. 
Macrophages, the cells that act to initiate an immune response and destroy pathogens are alerted 
to these foreign invading bacteria and will engulf the Mtb using various phagocytic receptors. 
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However, the parasitic nature of this relationship has just begun, for the Mtb have now found a 
niche inside the macrophage where they can survive and regenerate very slowly. Evidence has 
clearly shown that Mtb bacilli and host macrophages are essential to the pathogenesis of TB 
(Lee, Hartman, & Kornfeld, 2009). Within 2 to 6 weeks of this infection, macrophages recruit 
other accessory cells, most notably CD4 and CDS T -cells to activate cell-mediated immunity 
(Saunders & Cooper, 2000). The recruitment of inflammatory cells suround and help contain 
infected macrophages to limit spread of the bacilli. The result is containment of the bacilli and 
dead macrophages into a caseum, where a granuloma is formed. The granuloma will keep the 
bacilli in check perhaps forever, reactivate later in life, or it will break down and discharge 
bacilli into the airways causing necrosis of the bronchi and cavitation (Raja, 2004). One 
hypothesis about the importance of granuloma formation is that it provides a protective wall of 
macrophages and lymphocytes to surround infected cells, therefore when these infected cells die, 
the surrounding macrophages are in place to phagocytose the escaping Mtb and prevent 
secondary spread of infection (Saunders & Cooper, 2000). This complex protective immune 
response keeps Mtb from further transmission and is called latent TB infection (LTBI). Mtb can 
exist for many years or over ones’ life time encased in granulomas, and possess the genetic 
ability to survive in anaerobic environments in a state of dormancy (Canadian Tuberculosis 
Standards, 2007). Latent infection occurs in approximately 90% of all of those individuals who 
become infected with Mtb and they will never develop clinical illness or be infectious to others, 
unless reactivation of the latent infection should occur (Schluger, 2005). Empirically, LTBI is 
diagnosed through the use of the protein purified derivative (PPD) or tuberculin skin test (TST) 
that will induce a delayed hypersensitivity reaction from being previously infected with the Mtb 
(Cardona, 2006). It is estimated that only 10% of those with LTBI will ever go on to develop 
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active disease, this usually occurs in those who have underlying clinical risk factors such as HIV 
or other forms of immunosuppression (Schwartzman 2002). 
1.2 Reactivation of Latent Tuberculosis Infection (LTBI) 
LTBI truly represent one of the most challenging obstacles to overcome in order to gain control 
over TB. The inability of the immune response to totally eliminate Mtb atests to the remarkable 
evolution of this pathogen and its survival for thousands of years. 
Control of Mtb within the granuloma depends entirely upon successful immune responses, where 
we know this structure to be comprised of various immune cells (Chakravarty, Zhu, Tsai et ah, 
2008). In approximately 5% to 10% of latent infections the immune response fails and the Mtb 
that were onee held within the granuloma reactivate and develop into active TB disease (Flynn & 
Chan, 2001). Necrosis cause the granuloma to liquify and the protective walls lose structural 
integrity, allowing the necrotic material along with Mtb to drain out into bronchial pathways and 
nearby blood vessels, leaving behind a cavity (Knechel, 2009). This cavitary TB found in the 
pulmonary apex is the most frequent form of active TB found in adults, and evidence is widely 
accepted that these infections are the consequence of Mtb escaping from a lower base of the lung 
where Mtb favour the oxygen rich environment (Cardona, 2006). The Mtb are now able to infect 
new host cells and grow as extracellular pathogens in the various necrotic cavities that have been 
left behind (Lee et ah, 2008); this is essentially reactivation of LTBI into active TB disease. 
1.3 Risk Factors for Development of Active Tuberculosis Disease 
The integral functions of a successful immune response are required to keep Mtb contained to the 
granuloma. However, there are many illnesses and medications that result in immunosuppression 
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which can cause reactivation of an untreated latent infection. Over the last decade more research 
has developed in the areas of HIV and tumor necrosis factor-alpha (TNFa). 
1.3,1 Tuberculosis and HIV 
There are numerous studies throughout the literature on the higher incidence of TB among those 
who are HIV infected. The progression of a recently acquired TB infection into active disease in 
those who are HIV positive is rapid (Raja, 2004). Those at highest risk for reactivation of LTBl 
are persons with HIV coinfection; the association of the two opportunistic infections has shown 
to result in more than a one hundred-fold increase in risk (Schwartzman, 2002). The eo-infection 
with HIV is believed to bring about a reduction in CD4 T cells, which play a prominent role in 
the immune response to TB infection in granulomas (WHO, 2004). Conversely, TB infection 
also accelerates the progression of HIV disease to AIDS due to the macrophages that produce 
tumor necrosis factor-alpha (TNFa), a potent activator of HIV replication (see description of 
TNFa below) (Raja, 2004). On a global level, the impact of HIV on TB mortality rates has been 
substantial. TB is the most common cause of death in HIV infected individuals and will have an 
impact on TB control efforts in low-income and industrialized countries for years to eome 
(Canadian Tuberculosis Standards, 2007). Current surveillance reports from the Public Health 
Ageney of Canada (PHAC) indieate that HIV/AIDS is steadily rising in the Aboriginal 
population, particularly in women, representing an increase from 15.0% to 21.4% in the 
proportion of positive HIV test results; non-Aboriginal population has seen a decline from 75.7% 
to 58.4% (PHAC, 2007b). 
1.3.2 Tuberculosis and TNF-a 
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TNF-a, a cytokine, is a key mediator in the inflammaotry process of the immune system (Nash 
& Florin, 2005). TNF-a acts as a messenger to activate macrophages, which will in turn control 
Mtb replication and trigger an inflammatory respone to form proteetive structures (granulomas) 
in the lung (Marino, Sud, Plessner, et ah, 2007). This poses a dilema for those persons with LTBl 
who also suffer from chronie inflammatory diseases, most notably rheumatoid arthritis, chronic 
hepatitis and sarcoidosis. The expression of TNF-a is the driving force behind inflammation and 
the consequential damage to cartilage, joints and bone seen in rheumatoid arthritis (Nash & 
Florin, 2005). Controlled trials for TNF-a inhibitors in rheumatoid arthritis have shown great 
success in reducing signs and sypmptoms, improving quality of life and preventing further 
damage in these patients (Nash & Florin, 2005). A suspicion for reactivation of TB in patients 
with rheumatoid arthritis who are being treated with TNF-a inhibitors such as infliximab should 
be maintained by health care workers. The general rule of thumb for physicians is the necessity 
to screen patients for TB and LTBI and treat these conditions appropriately before initiating 
infliximab, a TNF-a inhibitor (Long & Gardam, 2003). This is of particular concern in Aborignal 
populations, as they experience a higher prevelence of arthritis and rheumatism when compared 
to non-Aboriginal Canadians (Shah, 2003). A Health Canada (2003) report on arthritis reported 
rheumatoid arthritis as the most prevelant chronic condition in Aboriginal communities, with 
27% of Aboriginal people over the age of 15 suffering from ehronic inflammatory arthritis 
compared to 16% in the non-Aboriginal population (Health Canada, 2003). 
Other risk factors for the development of active TB in those who have LTBI are presented in 
Table 1 below. This table shows that in addition to HIV and TNF-a, organ transplant 
immunosuppressant therapy, silicosis and chronic renal failure also increase the risk for TB. 
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Table 1. Risk Factors for Progression to Tuberculosis Disease 
Risk Factor Status Estimated Risk of TB Relative to Persons with No 
Known Risk Factors 
HIGH RISK 
• Acquired immunodeficiency syndrome (AIDS) 
• Human immunodeficiency virus (HIV) 
• Immunosuppressant therapy for organ 
transplantation 
• Silicosis 
• Chronic Renal Failure - hemodialysis 
• Carcinoma of the head and neck 
• Recent TB infection (< 2 years) 
• Abnormal chest x-ray, fibronodular disease 
INCREASED RISK 
• Treatment with glucocorticoids 
• Tumor necrosis factor (TNF-alpha inhibitors) 
• Diabetes mellitus (all types) 
• Underweight (<90% ideal body weight; for 
most persons this is a body mass index <20) 
• Young age when infected (0-4 years) 
• Smoker (1 pack/day) 
• Abnormal chest x-ray; granuloma 
















Infected person, no known risk factors, normal chest x- 
ray (low risk reactor) 
1 
Source: Courtesy of the Edition Canadian Tuberculosis Standards, 2007 (page 65) 
1.4 Active Tuberculosis Disease 
Approximately 10% of individuals infected with Mtb will develop active TB disease at some 
point over the course of their lifetime, usually within 2-5 years after infection (Lillebaek, 2005). 
Most TB disease occurs in the lungs where Mtb replicate and cause damage to the lung, this 
disease is known as pulmonary TB and is eonsidered infectious (Francis J Curry National TB 
Center, 2007). In approximately 15% of TB cases, the disease can spread to distant parts of the 
body and settle in organs, bone or other tissue. TB that develops in these areas is not considered 
infectious (Francis J Curry National TB Center, 2007). 
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The general symptoms of pulmonary TB disease include coughing for more than 2 weeks, fever, 
night sweats, fatigue, unexplained weight loss and sometimes hemoptysis (blood in sputum) 
(Canadian Tuberculosis Standards, 2007). The diagnosis of TB disease is confirmed in 
laboratory from a minimum of three culture samples, and a single positive culture for Mtb is 
generally adequate to define active disease (Canadian Tuberculosis Standards, 2007). Chest 
radiography is used to evaluate an individual who presents with pulmonary TB symptoms, and 
can not be used alone in diagnosis of TB disease (Canadian Tuberculosis Standards, 2007). 
1.4.1 Treatment of Tuberculosis 
Treatment for active TB disease is divided into two phases: (1) daily medications (initial phase), 
and (2) twice-weekly medication (continuation phase) (Canadian Tuberculosis Standards, 2007). 
Treatment with anti-tuberculous medications usually ranges between 6 to 9 months or until a 
minimum of 80% of the prescribed doses have been taken (Canadian Tuberculosis Standards, 
2007). Anti-tuberculous medications are prescribed for bacterieidal activity, sterilizing activity 
and prevention of drug resistance (Hershfield, 1999). The standard first line anti-tuberculous 
medications used are Izoniazid (INH), Rifampin (RMP), Pyrazinamide (PZA) and Ethambutol 
(EMB) (Canadian Tuberculosis Standards, 2007). 
Treatment for ETBl consists of treatment for 9 months with one drug, INH, which is taken in 
conjunction with vitamin B6 due to INH inference with pyridoxine metabolism, whieh produees 
peripheral neuropathy (Canadian Tuberculosis Standards, 2007). 
The preferred method for adherance of anti-tuberculous medications is with directly observed 
therapy (DOT). In a systematic review of DOT, (Cox, Morrow & Deutschmann, 2008) this 
strategy for TB control was recommended by the WHO in 1995 and has continued as an 
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important measure to complete treatment and cure patients with TB, while reducing the risk of 
drug resistance. To deliver DOT, a health care provider must watch the patient ingest the 
medication twice weekly for short term therapy. 
1.4.2 Epidemiology of Tuberculosis 
The World Health Organization (WHO) estimates that one third of the world is infected with 
mycobacterium TB; in 2006 there were 9.2 million new cases reported and 1.7 million deaths 
from TB (WHO, 2008). The emergence of multi-drug resistant (MDR) and extensively drug 
resistant (XDR) strains of TB is a genuine global threat that requires urgent attention and 
response. 
The national rate for TB in Canada continues to decline, and as of 2007 it was reported to be 4.7 
per 100,000 (PHAC, 2007a). This is a reflection of decreasing TB cases in the general Canadian- 
born non-Aboriginal population, as true incidence rates based on Canadian born Aboriginal 
populations remain consistently higher and have not decreased over the last decade (PHAC, 
2007a). The vast majority of TB cases in Canada remain with Aboriginal peoples and foreign- 
born citizens. In particular. Aboriginal people account for 20% of all cases reported in Canada; 
in Saskatchewan, the Northwest Territories, Nunavut and Yukon, they account for over 88% of 
TB cases, and for Manitoba the case rate is 66% (PHAC, 2007a). These provinces represent the 
highest current rates found in First Nation populations. Table 2 provides current rates of TB 
among Aboriginal and non-Aboriginal populations. 
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Table 2: Provincial and Territorial Tuberculosis Incidence Rates per 100,000 Population 







Incidence Rates per 
100,000  
Alberta 15 i: 3.2 
BC 41 32 6.4 
Manitoba 68 8.6 
New Brunswick 0.7 
NewFoundland .4 
Nova Scotia 0.7 
Ontario 13 49 5.1 
Prince Edward Island 
Quebec 22 55 
Saskatchewan 99 10.6 
Northwest Territories/Nunavut/Yukon 48 45.6 
Source: Tuberculosis in Canada: 2007 Report, Public Health Agency of Canada, page 15. 
The most interesting revelation has been the prediction for reactivation of TB done in a study by 
Clark & Vynnycky (2004) where analysis done between 1972 and 2000 showed 73% of TB 
cases in the 35 - 44 year age group were due to reactivation (Clark & Vynnycky, 2004). This 
could signify a variety of confounding factors, such as underlying chronic illness or poor 
treatment compliance. Non-complianee to TB medication regimens is one of the many 
challenges for TB control, where many studies find non-complianee to be associated with 
recurrence of TB (Picon, Bassanesi, Caramori, Ferreira, Jarczewski & de Borba Vieira, 2007). 
According to the most current 2007 TB Report for Canada, the Aboriginal population has a large 
percentage of younger TB cases (0-14 years) compared to Canadian born non-Aboriginals 
whereby those affected tend to be 65 years of age and older (PHAC, 2007a). This is of 
significance due to the age eategory, where it may be assumed some eases were most likely 
vaccinated with BCG and therefore should have had some protection against developing active 
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TB. A study by Cook et al., (2005) also confirmed that TB cases amongst Aboriginals tend to be 
younger, and they are more likely to be associated with a clustering of active TB cases. 
Clustering suggests recent or ongoing transmission within the community, as opposed to 
reactivation of old TB, and has been estimated to be 50% to 60% of TB cases. The study also 
concluded that BCG vaccination status had limited value in preventing clustering of TB cases 
and that more appropriate strategies to reduce transmission are required (Cook, et ah, 2005). 
1.5 History of Tuberculosis and Aboriginal People 
The terms used for “Aboriginal” people in Canada consist of three distinct groups; First Nations 
(North American Indians), Metis and Inuit and are recognized in the Constitution Act of Canada 
1982 (Canadian Tuberculosis Standards, 2007). 
The decimation of Indigenous populations due to infectious diseases with the arrival of European 
contact is well documented throughout the literature. The exposure of Canadian Aboriginal 
people to TB some 300 years ago contributed to extraordinary high mortality rates, as many as 
9,000 deaths per 100,000 people until the end of the 19th century (Blackwood, Al-Azem, Elliot, 
Hershfleld & Kabani, 2003). Approaching the twentieth century. First Nation reserves on the 
Canadian prairies had lost between 40% and 50% of their populations to disease, with average 
child mortality rates surpassing birth rates and mortality rates documented at 60 per 1000 
population for the Qu’Appelle First Nations in Saskatchewan (Eux, 1998). These high mortality 
rates are thought to reflect Aboriginal people’s lack of ancestral exposure to TB and consequent 
lack of antibodies for TB (Grzybowski & Allen, 1999). 
There are very few trials to examine TB and Aboriginal people from a historic perspective; 
however the study on the Qu’Appelle reserve in Saskatchewan examined how these Aboriginal 
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children became the subjects of a BCG vaccine trial in 1933; something that was extraordinary 
given the intolerant racial disparity that existed during that time (Lux, 1998). In 1921 the 
Saskatchewan Anti-tuberculosis Commission performed the first survey of school children for 
the province. Results found that 54% of the 1,184 non-Aboriginal children had a positive TST, 
whereas the sample of 192 Aboriginal children had a 92.5% positive TST rate (Lux, 1998). It 
was reported that the medical conditions of children admitted into the “Indian Industrial” schools 
or former “residential schools” was rarely questioned by sehool staff, while most children had 
TB. There was no attempt to isolate or ventilate classrooms or dormitories and transmission of 
TB was inevitable. In 1907 a school report noted that 69% of all ex -pupils were deceased 
subsequently upon discharge from the school. In all cases the cause of death was reported as TB 
(Lux, 1998). In spite of the deficiency of reliable TB data for the pre-chemotherapy era for 
Aboriginal people, Clark & Vynnycky (2004) were able to obtain an annual risk of infection 
(ARI) by using maximum likelihood methods, and is one of the few studies that attempt to 
estimate long-term trends in ARI. TB meningitis mortality rates and ARI trends from Statistics 
Canada since 1926 for First Nation children aged 0 -4 years were used to estimate the risk of 
primary, endogenous reactivation, and exogenous re-infection rates. Results concluded that the 
ARI during the pre-chemotherapy era likely ranged between 6% in 1926 and 21% in 1944 (Clark 
& Vynnycky, 2004). 
The first Canadian TB sanatorium opened in 1897, with only preventative methods of isolating 
infected patients and providing rest, nutrition and fresh air for rehabilitation. These hospitals 
were primarily for non-Aboriginal patients, and it was not until the end of 1953 that Aboriginal 
people were offered treatment and improved TB care (Grzybowski & Allen, 1999). The sanatoria 
experience and history of TB has influenced perceptions of TB treatment today, mostly from 
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those who experienced lengthy separations from family and community, loneliness and fear 
(Gibson, Cave & Doering, 2002). 
With the advent of anti-tuberculosis antibiotics to treat active TB by 1948, mortality rates of TB 
in the general population of Canada declined dramatically throughout the 1950’s, 60’s and 70’s 
(Health Canada, 1999). The mortality rate for Aboriginal populations also decreased during this 
timeline, yet Aboriginal populations on-reserve were still ten times more likely to have TB than 
non-Aboriginal Canadians (Health Canada, 1999). TB control activities on reserves sparsely 
existed before the 1980s, and were inconsistent from community to community as health services 
were not uniformly provided until 1982 (Smeja & Brassard, 2000). With higher rates of LTBI 
currently found in Aboriginal communities, these pools of TB infection have the potential to 
increase TB disease substantially, keeping the perpetual cycle of TB ongoing. If TB control 
efforts and resources are relaxed within these high risk communities, TB will continue to pose a 
public health risk for the future (Fitzgerald, Wang & Elwood, 2000). 
1.6 Bacille Calmette-Guerin (BCG) Vaccine 
As a component of the 1992 Tuberculosis Elimination Strategy for Aboriginal Peoples of 
Canada, the use of the Bacile Calmette-Guerin (BCG) vaccine was recommended as a strategy in 
communities that have a rate of new infections higher than 1 %, or with a high incidence of active 
TB disease (Health Canada 1999). The goal to reduce the incidence of TB disease to 1 per 
100,000 by the year 2010 is clearly not going to occur (Health Canada 1999). Questions remain 
as to the role of BCG in Canada and in the future for TB control. This section describes the 
history and current knowledge of the BCG vaccine. 
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BCG, a live attenuated vaccine that comes from the Mycobacterium bovis was initially 
developed at the Pasteur Institute in Paris is 1921 by Albert Calmette and Camille Guerin 
(Pereira, Dantas, Ximenes & Barreto, 2007). Current BCG vaccine strains are all descendants of 
the original M. bovis isolate and are used throughout the world (Canadian Tuberculosis 
Standards, 2007). BCG is currently the only TB vaccine available that provides protection for 
children against TB meningitis and disseminated TB, potentially fatal forms of TB. Thousands of 
lives have been saved over the past decades through BCG vaccination, particularly in most 
countries with a high burden of TB (WHO, 2004). There are approximately 172 high prevalence 
countries where BCG is routinely received, and over 3 billion doses are administered annually 
(Cook & Elwood, 2004). 
A single intradermal injection of the recommended dosage of BCG vaecine is administered over 
the deltoid region of the arm. The indication of BCG vaccination is the development of erythema 
followed by minimal ulceration that produces a noticeable scar (Canadian Immunization Guide 
2006). Unlike other vaccines that may provide ultimate protection, BCG does not prevent TB 
infection, but it is most effective at providing protection from dissemination of TB throughout 
the body. As a result, it is valuable for children at high risk of disseminated disease (Cook & 
Elwood, 2004). 
In a meta-analysis of the most current important studies to date on the efficaey of BCG and 
pulmonary TB, Barreto and colleagues (2006) found that there is common consensus on the first 
dose protection that BCG offers children against serious forms of TB meningitis and miliary TB. 
However there is controversy on whether BCG has any protective efficacy against the prevention 
of TB disease, and the duration of protective eoverage it provides (Barreto, Pereira & Ferreira, 
2006). In a meta-analysis of the literature, Brewer (2000) reviewed trials conducted over a period 
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of 46 years, analyzing data from 14 prospective trials and 12 case controlled studies. This meta- 
analysis revealed that vaccination with BCG significantly reduced the risk of TB by an average 
of 50%, which supports the use of BCG in those children at risk. Yet there remains uncertainty 
and inconsistencies in the literature as to how long the benefit of BCG lasts (Brewer, 2000). The 
WHO position statement on the duration of BCG protection was that the vaccine gradually 
declines with time and is likely to be lost after 10-20 years (WHO, 2004). 
A study conducted on long term efficacy of BCG vaccine in American Indians and Alaska 
Natives (Aronson, Santosham, Comstock, et ah, 2004) used retrospective records reviews and 
supplemental interviews with some original participants of a placebo-controlled trial of BCG 
more than 50 years ago. The overall incidence of TB was calculated to be 66 and 138 cases per 
100,000 for the BCG vaccine group and placebo group, respectively. Vaccine efficacy of 52% 
protective coverage from TB meningitis and miliary TB was reported, which compares favorably 
with many other trials (Brewer, 2000). In the study conducted by Aronson and colleagues 
(2004), the duration of BCG was studied, and was found to have protective benefit lasting 
between 50 and 60 years after one single dose. This represents the longest follow-up trial to date, 
where most other controlled trials have reported 15 to 20 years at the most (Aronson, et ah, 
2004). This finding also supports the use of BCG in high risk children, or those who are 
continually exposed to active TB. 
Barreto and colleagues (2005) recently conducted a randomized follow-up trial of children in 
two cities in Brazil, and chose one city closer to the equator due to the evidence that BCG 
efficacy tends to be lower in populations where environmental mycobacterium exposure is 
greater. This study also reported substantial protection (39%; 95% Cl 9-58) of neonatal BCG 
against serious forms of childhood TB some 15-20 years after vaccination (Barreto, M.L., 
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Cunha, S., Pereira, S., et al., 2005). The Canada Communicable Disease Report (2004) 
concluded that BCG efficacy is estimated at approximately 50% for prevention of TB disease, 
64% for meningitis and up to 80% for disseminated disease in infants. 
However, with such a variation between studies, the duration of BCG protection will most likely 
be debated for years to come. It is obvious that BCG plays a minimal role in preventing the 
transmission of TB as a public health measure, and as such its routine use has been questioned. 
1.6.1 Factors Related to the Decision to Discontinue BCG in British Columbia First Nation 
Children 
The decision to discontinue routine BCG vaccination in First Nation populations was made with 
deliberation based on the evidence of serious implications for continued BCG use and the need 
for a safer and more effective alternative to BCG vaccination (Clark & Cameron, 2006). While 
research has shown that the BCG vaccine protects vulnerable populations from serious forms of 
TB, the discontinuation of routine BCG use in First Nation children was prompted by adverse 
event notifications and complications of the vaccine, which resulted in higher rates of 
disseminated BCG disease than what was expected - many of which were fatal (PHAC, 2004a). 
Rates of pediatric TB disease have declined rapidly in the last ten years, and interventions sueh 
as early detection and treatment may be more appropriate now (Dawar, Clark, Deeks, Walop & 
Ahmadipour, 2003). In this section, discontinuation of BCG vaccination is discussed primarily in 
relation to low incidence rates of TB and adverse effects caused by the vaccine. 
1.6.1.1 Low Incidence Rates 
In Canada, the use of BCG is currently limited to on-reserve First Nation and Inuit children as 
part of a TB elimination strategy to reduce the disproportionately high TB rates in this 
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population, and is not a routinely recommended vaccine for the general Canadian population 
(Canadian Tuberculosis Standards, 2007). Canada, like many other developed nations chose to 
evaluate the efficacy of BCG in light of the declining incidence of TB and changing 
epidemiology. 
As of 2003, the BCG vaccine has been discontinued from all BC First Nation neonatal 
vaccination schedules though other provinces, with the exception of the Atlantic Provinces (i.e., 
New Brunswick, Newfoundland, Labrador, Nova Scotia, Prince Edward Island) and Quebec who 
continue to offer it (PHAC, 2007d). In the Atlantic Provinces, the decision to discontinue the 
BCG vaccine was related to very low TB incidence rates (i.e., range from 0 to 4 cases over the 
past 10 years) which included First Nation communities in New Brunswick and Nova Scotia; 
Quebec had discontinued routine use of BCG in the mid-late 1970s for school students, and has 
discontinued BCG in all First Nation communities as of 2005 (PHAC, 2007d). 
The province of Alberta is also moving to systematically withdraw the use of BCG; careful 
review of the evidence to support the BCG policy change with minimal impact to First Nation 
communities have been underway. BCG has been discontinued in 41 of 44 First Nation 
communities as of 2007 (PHAC, 2007d). A study by Long and colleagues (2004) examined the 
occurrence of pediatric TB in Alberta First Nations over a period of 10 years from 1991-2000; 
within two separate micro-epidemics that were reported, there was scant evidence that BCG 
reduced the severity of disease. Disease rates in the BCG vaccinated close pediatric contacts 
were 7/20 (35.0%) and unvaccinated pediatric contacts were 13/39 (33.3%) respectively. The 
results from the pediatric cases concluded that disseminated disease was found in 0/11 BCG- 
vaccinated pediatric cases, and 1/20 BCG-unvaccinated cases, and all cases completed 
satisfactory course of treatment. The recommendation to use enhanced surveillance for detection 
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of infection and disease in children by serial tuberculin skin testing as an alternate to BCG was 
therefore proposed. It is evident in Long’s work that maintaining BCG coverage does not 
influence burden of disease among children, even though it does reduce individual childhood 
morbidity. Consequently, enhanced surveillance and screening in children would also serve as a 
marker for on-going transmission in the community (Long et al., 2004). Targeted TB screening 
of children in high risk populations has also provided evidence of decreasing the burden of TB 
further. A recent study by Brassard and associates evaluated a school based TB screening 
program in Montreal for immigrant children aged 4-18 years. Investigation also included 
household associates and other family members with previous TB information. The study results 
found 542 (21%) schoolchildren with a positive TST, and 342 were started on therapy. There 
were 555 associates skin tested, of which 211 (38%) were found to be TST positive. Of these, 
131 had chart reviews for previous TB information, and 108 (82%) were started on treatment. 
Multivariate analysis also verified that screened schoolchildren who had at least 2 family 
members also brought in for screening was positively associated with adherence to treatment, 
which further reduced risk of transmission. A cost-benefit analysis also estimated that 36.1 cases 
of active TB were prevented by the school-screening and resulted in substantial health care 
savings (Brassard, Steensma, Cadieux & Lands, 2006). 
Evidence from case study analysis of various associative investigations by Moonan, Quitugua, 
Cox, Do, and Wiess (2002) revealed that children very seldom transmit TB bacilli to others due 
to the rarity of having cavitary lung disease and ability to produce a forceful cough to expel and 
aerosolize the droplet nuclei required for transmission. When a child is found to have a positive 
TB skin test (TST), this indicates recent infection that usually comes from an adolescent or adult 
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family member. Investigation and prompt treatment for those infected will prevent further 
unnecessary transmission. 
However, there will remain circumstances where the benefits of BCG vaccination to prevent 
serious forms of TB in children still outweigh any risks. For example, a retrospective population 
study conducted in Greenland by Soborg, Soborg, Pouelsen, Pallisgaard, Thbyo, and Bauers 
(2001) found that use of mass BCG vaccination in Greenland, which had one of the highest 
incidences of TB in the world (2300 per 100,000 in 1955), greatly reduced TB rates to an 
acceptable level (i.e., 25 per 100,000 by 1985). BCG vaccination at birth had always been 
provided in this country until 1990 when it was discontinued. After discontinuation, the greatest 
increase of TB cases were noted among children aged 0-7 yrs; two cases of fatal TB meningitis 
occurred during this time and prompted reimplementation of BCG in 1996. Between 1990 and 
1997 an increase in TB rates had doubled and reached 172 per 100,000 by 1997, (Soborg et ah, 
2001). This study found groups of children born between 1990 and 1996 who did not receive 
BCG vaccine had the greatest increase in incidence from 12 per 100,000 to 171 per 100,000, 
showing that recent transmissions were occurring. Much of the increases were partly due to 
micro-epidemics located in small isolated Native settlements where multi-faceted challenges of 
medical staff shortages, weak case finding and treatment, over-crowded housing, and greater 
susceptibility due to lack of vaccination increased risk (Soborg et al., 2001). It was noted that 
Greenland had no reporting system for monitoring TB treatment results or quality control 
measures in place at the time of this study. Review of the International Union against TB and 
Lung Disease (lUATLD) criteria for shifting mass BCG campaigns to more selective programs 
specifies that a surveillance system must be in place; lack of any kind of surveillance in 
Greenland may very well have added to the consequential transmission of TB. 
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In other industrialized countries of low-incidence, immigration of populations from high TB 
endemic areas is increasing and changing the epidemiology of TB. Efforts in TB control 
programs are now primarily restricted to a few high-risk groups (Nguyen, Proulx, Westley, 
Thiebert, Dery & Behr, 2003). A recent study by Romanus (2006) investigated the surveillance 
of BCG vaccination in Sweden between 1989 and 2005, and found reason to continue selective 
BCG vaccination policies, even though Sweden has one of the lowest incidences of TB in the 
world (6.4 per 100,000 in 2005). General neonatal BCG vaccination was discontinued in 1975 
due to frequency of BCG induced osteomylitis (29 cases per 100,000) and changed to selective 
vaccination of those at risk. From 1979 to 1991 there were four cases of serious disseminated 
BCG infection; three were caused by severe combined immunodeficiency (SCID). In 1993 the 
recommendation to postpone BCG vaccination until 6 months or older was implemented. There 
have been no cases of disseminated BCG infection reported since 1991. The BCG coverage for 
children defined as a risk group (those children bom to foreign-born parents) was estimated to be 
88% for children born from 1998 to 2002. It was expected that the 1975 policy change would 
have affected the Swedish born children under five years of age who and were no longer 
vaccinated. However, even though there was a temporary increase in the annual incidence of TB 
in children, the rate had remained low varying between 0 and 1.9 per 100,000 during 1975 to 
2004. Romanus’ (2006) study supports the policy that restricting BCG vaccination to those 
children at risk (being born to foreign-born parents) has reduced the incidence of TB in those 
children, and the majority of Swedish born unvaccinated children still retain minimal risk of 
infection. Foreign-born age specific TB incidence rates are shown to be highest in the age group 
of 18-44 years, which constitutes 58 per 100,000 populations. This may pose some futuristic 
challenges for TB control in Sweden. With such high incidence rates in child-bearing age 
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groups, the increased risk of exposure for children in these families will need to be monitored. 
In the Swedish-born population, the incidence was shown to be 2.0 per 100,000 (Romanus, 
2006). In contrast, the current proportion of foreign-born TB patients has increased by more than 
70% from 34% in 1989 (Romanus, 2006). As of 2005 the estimated incidence of foreign-born 
TB has increased to 38 per 100,000, and immigration from African born populations has 
revealed an incidence of more than 200 per 100,000 (Romanus, 2006). Compared with the age 
specific Swedish group rate of 0.6 per 100,000, it is obvious that the majority of TB cases for 
Sweden are among the foreign-bom. 
These findings should serve as a reminder that even though Canada has a low incidence rate of 
TB compared to other countries, the rate is a reflection of the rate among the Canadian bom non- 
Aboriginal population (PHAC, 2007a). Aboriginal communities must continue to be a priority 
for vigilant case finding and treating sources of infection as they continue to be at high risk 
(Fitzgerald, Wang & Elwood, 2000). 
1.6.1.2 Adverse Effects 
The Public Health Agency of Canada issued a statement in 2004 that revealed serious adverse 
events associated with the BCG vaccine had occurred among First Nation children (PHAC, 
2004a). A review of the Immunization Monitoring Program-Active (IMPACT) identified 21 
BCG vaccine related adverse events between 1993 and 2002. 15 of these cases were deemed 
serious (person died or was hospitalized for 3 or more days) and 14 cases were associated with 
the BCG vaccination. Five First Nation children died from disseminated BCG disease (PHAC, 
2004a). Disseminated BCG disease is extremely rare, occurring in 1 per 3.4 million infants who 
have been vaccinated with BCG; however it is associated with a high mortality rate especially in 
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those with underlying immune deficiency diseases (Huang, Shyur, Weng, Chi, Tzen & Huang, 
2005). Contraindications are clearly outlined not to vaccinate people who may have congenital 
immunodeficiency, symptomatic HIV infection, altered immune status or secondary immune 
function due to treatment with various immuno-suppressing medications (Canadian Tuberculosis 
Standards, 2007). In the case of these First Nation children, all had immunodeficiency and 
concurrent infections that were not identified prior to being given the BCG vaccination which 
resulted in a greater number of First Nation children with disseminated disease than anticipated 
from reported rates in other studies (Deeks et ah, 2005). The Canadian Communicable Disease 
Report (PHAC, 2004a) suggests that immunodeficiency states may be more common within the 
First Nation population than previously known. Although there is prenatal screening for HIV 
available that would minimize contraindicated vaccination with BCG, there is still risk present 
for those suffering from congenital conditions such as severe combined immunodeficiency 
(SCIDS) that may not be detected until dissemination has already occurred (Cook & Elwood, 
2004). Therefore the risk of disseminated BCG infection must be considered when assessing the 
risks and benefits of routine BCG immunization in these children. 
The review by PHAC (2004a) calculated an extremely high estimated incidence of adverse 
events occurring in First Nation children when compared to global estimates (see Table 3 for 
comparisons of First Nation children and global estimates for disseminated disease). 
Table 3. Estimated incidence of adverse events associated with BCG vaccine in First 
Nations children, 1996-2000* 
Adverse event (AE) Adenitis Osteitis Dissemination 
Absolute number of AE 11 1 3 
Canadian First Nations on-reserve AE/million 








Global estimates of AE/million doses BCG 387 1.7-72.9 0.19-1.56 
*based on 14,622 doses administered when compared to global estimates. 
Source: Public Health Agency of Canada (2004), page 6. 
1.6.1.3 Other Rationale 
In this section, other rationale used to discontinue the BCG vaccine are briefly presented. In 
particular, issues related to coverage, long-term effectiveness, and interpretation of tuberculin 
skin tests are discussed. 
Coverage was among the issues that influenced the decision to discontinue routine BCG 
vaccination of First Nation children in British Columbia., Among First Nation communities that 
were eligible for the vaccine, only 25% were found to be actually administering the vaccine 
(Cook & Elwood, 2004). An analysis to review the uptake of BCG in First Nation communities 
was conducted by Dawar and associates (2003), where results suggested extensive variance in 
coverage between communities and within provinces. This study concluded that BCG coverage 
has been in decline since the late 1990s, and that uptake varied from 35% to as high as 98.5% 
across the country (Dawar et ah, 2003). Additional studies on BCG vaccination among First 
Nations in Saskatchewan also reported low uptake of vaccination coverage (50%), signifying 
many infants have not received BCG vaccination as indicated by Health Canada 
recommendations (Reid, Ward, Marciniuk, Hudson, Smith & Hoeppner, 2007). 
The long term effectiveness of the BCG vaccine also contributed to the decision to discontinue. 
The role of BCG in preventing serious forms of TB meningitis and disseminated TB in children 
is well established; however this defense wanes over time, to what extent is not clear as there 
remains controversy over the exact protective duration of BCG. BCG does not offer protection 
from adult acquired primary infection, nor does it protect from reactivation of latent pulmonary 
infection later in life, although it has been found to limit the spread of bacteria after infection 
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(Menzies, Tannenbaum, & FitzGerald, 1999; WHO, 2004). BCG is not likely to have any 
significant impact on transmission of TB within a population and thus limits its usefulness in TB 
control programs. In high and low incidence countries, TB elimination efforts focus primarily on 
case finding and prompt treatment of patients with active disease to prevent transmission, but 
more emphasis needs to occur equally to treat those with LTBI (Lillebaek, 2005). 
One last factor that informed the decision to discontinue BCG vaccination programs is 
interpretation of tuberculin skin test (TST) in a person who has had a BCG vaccination. The 
standard use of the TST is monumental in identifying those with TB infeetion; however, BCG 
vaccine is known to interfere with accurate TST results, depending on when the individual 
received the BCG vaccination (Canadian Tuberculosis Standards, 2007). Therefore, many 
countries have discontinued BCG vaccine in order to preserve the diagnostic significance of the 
purified protein derivative (PPD) as an indicator of previous mycobacterium TB infection 
(Barreto et ah, 2006). Further, it is generally accepted that people who have been vaccinated with 
BCG in the first year of life and are given a TST at age 10 years or older will have an accurate 
reaction regardless of BCG vaccination status, when it is administered after 12 months of age, it 
can be considered the likely cause of a positive TST (especially among non-Aboriginals and 
immigrants from a low risk areas) (Canadian Tuberculosis Standards, 2007). 
1.6.2 Criteria for Discontinuing the BCG vaccine 
In low-burden countries, the choice to limit BCG vaccination has been recognized by the World 
Health Organization (WHO, 2004). The International Union Against Tuberculosis and Lung 
Disease (lUATLD) have developed criteria defining low endemicity for those countries choosing 
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to amend immunization schedules from universal to selective BCG vaccination (WHO, 2004) 
(see Table 4 for criteria). 
Table 4 Criteria for Low Endemicity 
□ An average annual notification rate of smear-positive pulmonary TB cases below 5 per 100,000; or 
□ An average notification rate of TB meningitis in children aged five years and below 1 per 10 million 
population during the previous five years; or 
□ An average annual risk of TB infection below 0.1%. 
Source: World Health Organization, Epidemiological Record 2004, page 38. 
Guidance for the decision by any country to discontinue a routine BCG vaccination program is 
based on recommendations from lUATLD (WHO, 2004). Discontinuation of BCG should be 
considered when (1) an effective notification system is in place; and (2) either the average annual 
notification rate of smear-positive pulmonary TB is <5 per 100,000 or the annual notification 
rate of TB meningitis in children <5 years of age is <1 per 10 million population over the 
previous 5 years or the average annual risk of TB is 0.1% or less (PHAC, 2004a). 
Most countries with a low incidence of TB have chosen to discontinue universal BCG programs 
and implement selective programs to target those with higher risk factors for TB. Appendix 1 
provides additional information on BCG profiles from various countries (i.e., Finland, Germany, 
Greenland, Spain, Sweden, UK, and USA) (World Atlas of BCG Policies and Practices, 2009). 
1.6,3 Replacing BCG Vaccination with Enhanced Screening Surveillance 
Although Canada has met the lUATLD criteria as a low-burden population for TB and can 
therefore safely discontinue routine BCG vaccination programs, it is recognized that TB 
continues to be problematic in some First Nation communities where microepidemics or 
clustering occurs (Dawar et ah, 2003). Therefore, the replacement of BCG with enhanced 
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surveillance is crucial to monitoring trends in this population, and should consist of intensified 
case finding, treatment of active disease, screening and treatment for LTBl, and supervised 
directly observed therapy (DOT) for those taking medication (Canadian Tuberculosis Standards, 
2007). To evaluate the effectiveness of enhanced surveillance, the BCCDC has a protocol to 
provide surveillance to monitor children and communities during the transition from vaccination 
to enhanced screening (Cook & Elwood, 2004). The number of active TB cases has defined the 
criteria for screening in First Nation communities as follows: 
“1. Annual community TB screening for all on-reserve band school children in grades 1 & 6, 
employees of health centers, band schools, daycare and pre-school, and those at higher risk with 
HIV/Aids, kidney dialysis, cancer, lymphoma, leukemia, organ transplants, low body weight, 
diabetes, and those on immune-suppressing medications. 
2. Those communities with 1 or more cases of infectious TB disease in the past five years will 
have a community wide screening every 2 years for the entire community, including all grades 
for on-reserve band schools. Children born after June, 2000 will receive annual TB screening at 
10 months, 2, 3, 4 & 5 years of age” (First Nation and Inuit Health TB and Immunization, 2009). 
Periodic evaluation of surveillance systems will enable BCCDC to decipher which communities 
have and do not have active cases, the extent to which screening is occurring, and if not, what is 
impeding screening efforts in a community. 
1.7 Defining Enhanced Surveillance 
Enhanced surveillance refers to the systematic collection of data, consolidation and evaluation of 
this data, and prompt dissemination of these trends, specifically to those who implement 
programs and policy (Canadian Tuberculosis Standards, 2007). In particular, the objectives of 
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TB surveillance programs are to: (1) guide health interventions; (2) estimate trends; (3) identify 
high risk groups; (4) monitor changes in the pattern of disease transmission; (5) evaluate 
prevention efforts and strategies; and (6) conduct related research (Canadian Tuberculosis 
Standards, 2007). 
Collection of TB surveillance data is a critical function of public health; without valid 
surveillance data there is a risk to misinterpret true epidemiology of TB, compromise program 
planning, evaluation and research, provide misguided interventions and inappropriate allocation 
of resources for TB prevention (Sprinson, Lawton, Porco, Flood & Westenhouse, 2006). 
Providing enhanced screening activities to those considered at high-risk for TB in endemic 
communities alongside case detection and improved compliance with treatment of LTBI will 
have considerable impact on transmission (Health Canada, 1999). 
1.7.1 Setting the Stage for Enhanced Surveillance in British Columbia 
The National Tuberculosis Elimination Strategy for Aboriginal Peoples of Canada was 
introduced in 1992 (PHAC, 2004a). However, elimination is currently not seen as a realistic 
goal; consequently, it was recommended in 2005 that the goal be changed to a target incidence 
rate of 3.6 per 100,000 by 2015; to achieve this goal, an annual reduction of 3.3% will be 
required between 2007 and 2015 (PHAC, 2007a). 
The control of TB and consequential reduction in incidence rates can be achieved with delivery 
of the basic objectives outlined in the Health Canada TB Program, whieh include: 1) detect and 
diagnose TB infections among those exposed to infectious cases and prevent the transmission of 
disease to other community members, 2) provide treatment to those with active and latent TB, 3) 
support health care workers and communities with prevention edueation and awareness to 
understand TB (Health Canada, 2007). 
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TB services for British Columbia First Nation communities are administered through the 
centralized BC Center for Disease Control (BCCDC). A unique collaboration and protocol exists 
between First Nation & Inuit Health and BCCDC that increases support, treatment, and 
surveillance of LTBI and active TB cases in all First Nation communities. Health Canada does 
not have public health legislation that applies to federal on-reserve communities, therefore they 
must work with provincial health governments and First Nation communities to regulate public 
health activities (Health Canada, 2007). 
Currently, the BC Center for Disease Control uses the Public Health Information System (iPHIS) 
to capture TB data for BC First Nation clientele. Information pertaining to TB status, BCG 
history, gender, date of birth, TB #, treatment plan, medication, completion of treatment, 
radiology results, laboratory results, contacts and TST screening activity is captured in this 
system (PHAC, 2007e). 
For the purpose of evaluation, TB surveillance data is essential for tracking and monitoring 
changes in communities. The Center for Disease Control National Prevention Information 
Network (CDC NPIN) endorses TB surveillance to enhance efforts to prevent TB, improve 
allocation of resources to treat, and evaluate impaets of public health interventions (CDC TB 
Evaluation Handbook, 2006). 
L 7.2 Challenges of Tuberculosis Control 
There are numerous impediments that lay outside the domain of enhanced surveillance and 
public health that continue to challenge the control of TB in Aboriginal communities. New 
initiatives to address TB in Aboriginal communities with acknowledgement of the underlying 
social and economic determinants of health are urgently needed (Cook & Elwood, 2008). 
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Education and awareness about TB is erucial for the success of prevention and treatment efforts 
in any high risk group, and has often been a challenge for public health (Brassard, Anderson, 
Menzies, Schwartzman & Macdonald, 2008). Studies exploring Aboriginal knowledge, 
awareness and experience with TB have been few, and those that were undertaken have found 
similar themes indieating lack of TB knowledge. A reeent study by Brassard and associates 
(2008) had conducted a tuberculin screening for urban Aboriginal people in Montreal and 
subsequently structured interviews to explore partieipants’ knowledge and perceptions of TB. A 
sample size of 164 Aboriginal participants were recruited, and approximately one-third reported 
knowing very little about TB, including transmission, signs and symptoms, risk factors and 
cause. While the majority of participants felt that TB was not openly diseussed in community or 
at home, half of the respondents were not worried about eontracting TB. This study concluded 
that there was a general lack of knowledge and many misconceptions about TB within this 
sample (Brassard et ah, 2008). 
Considering that many of these respondents could potentially be at risk for active TB, this lack of 
knowledge may also contribute to on-going transmission. Many people who are started on 
treatment have sometimes misunderstood TB information by a provider or the terminology of 
drug resistance, and this has led to complications in management of the disease (Hoeppner & 
Marciniuk, 2000). Health education is an important component of TB control, and helps to 
ensure that people are able to recognize the signs and symptoms of TB and take measures to 
counteraet the disease in a timely manner before infecting others (Gibson et ah, 2001). In a study 
by Gibson, Cave, and Doering (2001) the soeiocultural factors affecting TB treatment and 
prevention in Aboriginal populations in Alberta were explored. Their findings revealed a lack of 
understanding about TB in the Aboriginal communities. They also found a relationship between 
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knowledge and perceptions of TB, where those who did not know much about TB had a more 
negative perception (Gibson, et ah, 2001). This study reinforced the importance of providing 
education that is acceptable, respectful and meaningful in one’s culture. 
Housing conditions, lack of housing and overcrowding in many First Nation communities have 
been identified as a common problem for TB control (Clark, Riben & Nowgesic, 2002). A report 
issued by PHAC (2007e) confirms that housing conditions serve as risk factors for TB infection 
and disease. Overcrowded houses combined with poor air ventilation have been implicated in the 
transmission and outcome of TB; in particular, an increase of 0.1 persons per room increased the 
risk of two or more cases of TB in a community by 40%. This is important as the current average 
number of persons per room for First Nation people is 0.6, which is 20% greater than in the 
general Canadian population (PHAC, 2007e). 
Basic public health services in many small remote First Nation communities are increasingly 
vulnerable to environmental changes, climate change and limited natural and economic resource 
bases (Furgal & Seguin, 2006). A study of TB screening programs in a First Nation community 
in James Bay by Smeja & Brassard (2000) found that the high turnover of nursing and medical 
staff can negatively impact TB control in various ways. New practitioners may not be familiar 
with TB or its’ epidemiology in Aboriginal communities, and this lack of awareness can lead to 
delays in diagnosis and potential outbreaks. A greater number of reactivations of TB is to be 
expected in the near future due to changes in diet and lifestyle that have resulted in massive 
increases of diabetes; one of the known risk factors for progression to active TB (Smeja & 
Brassard, 2000). 
TB control programs in some high prevalence First Nation communities also have challenges 
with the movement of people from reserves to local communities and visa versa, which is a 
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major risk to default on treatment (Fitzgerald et al,, 2000). The movement from rural to inner 
cities by Aboriginal people is concerning as studies have found that Aboriginal people form 
some of the poorest residents of Canada’s inner cities (Fitzgerald et ah, 2000). The more 
northern remote communities also have social networks through which TB transmission occurs 
that extend beyond the reaches of a local public health unit; individuals regularly travel out from 
one village to the next (Nguyen et ah, 2003). 
More recently, other contributing causes to TB transmission have been uncovered by Cook & 
Elwood (2008) in a study on the burden of TB in Aboriginal communities in BC. Specifically, 
they found that a large outbreak of TB was related to delays in diagnosis and seeking treatment, 
as well as to substance abuse (Cook & Elwood, 2008). 
1.7.3 Evaluation of Enhanced Surveillance Screening in First Nation Populations 
A review of the literature in Pub Med and the Cochrane Library was undertaken to find evidence 
and literature pertaining to discontinuation of BCG and evaluation of enhanced surveillance 
screening specific to First Nation communities; no evaluations were identified other than studies 
supporting the discontinuation of BCG in First Nation communities (see Appendix 2 for a list of 
keywords used in the search). 
However, there is a plethora of literature on evaluation methods, surveillance systems, effective 
TB programs and screening in high-risk and hard-to-reach populations. With this information, a 
framework for evaluation specific to this population and based on the best available evidence can 
be accomplished. 
The long term ambition of any TB control programs is evident: to improve control measures and 
eventually eliminate TB by using a diverse range of objectives to meet this goal (CDC TB 
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Program Evaluation Handbook, 2006). The priority for TB control is early detection of those 
with TB disease, followed by prompt treatment. Prevention of TB is also accomplished by early 
identification of those with LTBl and the provision of chemoprophylaxis to reduce the risk of 
future transmission (Yuan, Richardson, & Kendall, 1995). 
Evaluations of TB programs are essential to program management, providing a framework for 
performance indicators, generation of knowledge, resource allocation, and assessment of 
outcomes (Bartholomew, Parcel, Kok, & Gottlieb, 2001). Successful evaluations are a work in 
progress, monitoring implementation and outcome factors as they are being conducted. The 
quintessential components of a TB program evaluation framework include: (1) stakeholder 
engagement; (2) description of the purpose and elements of the screening program; (3) detailed 
information on the evaluation design; (4) data collection; (5) data analysis and interpretation; and 
(6) dissemination (CDC TB Program Evaluation Handbook, 2006). 
1.8 Goal of this paper 
The purpose of this paper is to provide an evaluation framework for the enhanced TB 
surveillance screening of First Nation children in British Columbia that is culturally relevant to 
First Nation populations. To do so will entail a broad framework of components that are based 
on current evidenee available in TB control programs and Aboriginal/First Nation health. The 
primary components of the framework will consist of 1) stakeholders, 2) program description, 3) 
evaluation design, 4) data analysis and interpretation, 5) dissemination of results. 
2. Stakeholder Engagement 
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There are a wide variety of stakeholders with a vested interest in TB programs who will be 
potentially affected by the evaluation (CDC TB Program Evaluation Handbook, 2006). FNIH, 
BCCDC and First Nation communities work in partnership to deliver and receive TB services; 
therefore they are identified as primary stakeholders in the evaluation process. During the 
evaluation for discontinuation of BCG vaccine programs for First Nations, stakeholders advised 
FNIH to both be very careful and methodical when planning for discontinuation of BCG in 
communities that were at particular risk, and to ensure that TB program elements and resources 
were in place prior to the decision to discontinue (PHAC, 2004a). Participation by persons 
involved in program operations, persons served or affected by the program and consumers of the 
evaluation findings for funding are all priority stakeholders who contribute diverse perspectives 
(CDC TB Program Evaluation Handbook, 2006). 
Of utmost importance is the engagement and collaboration with Aboriginal people for whom this 
service is intended. Current activities to address TB in Indigenous populations include 
collaboration on a strategic framework that promotes Indigenous specific approaches and 
methodologies for the control and eradication of TB (A Global Indigenous Peoples’ Initiative to 
Stop TB, 2009). The control of TB requires a specialized centralized program with TB expertise; 
however it must include a relationship and partnership with Aboriginal communities that account 
for socioeconomic conditions and cultural characteristics unique to those communities 
(Hoeppner & Marciniuk, 2000). In order to achieve TB control and elimination goals, there will 
need to be a greater degree of community partnership delivered in a culturally sensitive manner 
that has not been practiced in the past (Fitzgerald et al., 2000). One strategy of the Indigenous 
People’s Initiative to Stop TB is to incorporate Indigenous cultural values, traditions and life 
ways in TB control and advocacy activities by: 1) ensuring policy and action are informed by 
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cultural Indigenous people, 2) encouraging TB programs to become aware of and respect the 
significance of language, culture, traditions and beliefs, 3) ensure that respect, empowerment, 
capacity building, education and training are fundamental to Indigenous community engagement 
modalities (A Global Indigenous Peoples’ Initiative to Stop TB, 2009). 
While there are a large number of stakeholders, not all need to be available throughout the entire 
evaluation process. Depending on their roles, some may want to be involved at different times in 
the process. For example, program managers, supervisors, community health representatives, 
nurses and other staff may want to be more involved in defining evaluation questions and using 
the results for program modification, whereas others may help collect data or advocate for the 
program itself (CDC TB Program Evaluation Handbook, 2006). 
Stakeholders at the community level play an important role in helping to reduce TB 
transmission, case finding and treating clients with TB. In Hoeppner & Marciniuk’s article on 
TB and Aboriginal Canadians it was established that Aboriginal community lay-workers were 
more effective in increasing complianee with TB treatment than non-Aboriginal health care 
workers, which highlights the value of compatibility, sensitivity and familiarity of cultural 
differences (Hoeppner & Marciniuk, 2000). There is enormous potential at the community level 
to engage and create action plans with local health care providers to reduce TB. 
3. Description of the Program 
A vital piece of planning an evaluation includes knowing exaetly what was done when carrying 
out the project and why it was done; without this information, it is impossible to select 
appropriate and valid measures or to show causal relationship between project activities and 
outcomes (W.K. Kellogg Foundation, 1998). Further, within the description of the program, the 
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scope of the evaluation should reflect the system’s eurrent standard of eare and publie health 
practiee, as well as how the program is organized in order to fully understand internal and 
external faetors affecting program outcomes (CDC TB Program Evaluation Handbook, 2006). 
The principles of eare for persons who have or are suspected of having TB are based on the 
International Standards for Tubereulosis Care 2006 (ISTC), and are currently endorsed by the 
Public Health Agency of Canada, the Canadian Thoraeic Soeiety and the Canadian Tuberculosis 
Committee ( Canadian Tubereulosis Standards, 2007). The BCCDC TB Services for Aboriginal 
Communities (TBSAC) program provides TB services based on these standards of what should 
be done to provide quality TB care (Appendix 3 provides a summary of recommendations from 
the International Standards for Tubereulosis Care, 2006). All provinces and territories of Canada 
are legally required to report TB eases to public health authorities, who in return will provide 
select non-nominal data to the Canadian TB Reporting System (CTBRS) for annual TB reports 
(Canadian Tuberculosis Standards, 2007). 
The task of creating a elear deseription of the TB program goals and objectives has already in 
part been accomplished with national and global indieators, as most TB programs have been in 
place for decades (CDC TB Program Evaluation Handbook, 2006). The description of the TB 
program should inelude the following components: 1) explanation of the community’s need for 
the TB program, 2) depietion of the target audience for TB program services, 3) the context in 
which the program operates, 4) objeetives of the program, 5) program’s stage of development, 6) 
program resources/inputs, 7) all program activities, and 8) results or outcomes of the program 
(CDC TB Program Evaluation Handbook, 2006). 
It should be noted that no matter how well thought out the program or utilization plan may be, if 
interaction with the target population is not happening, or does not happen according to the 
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parameters required to ensure success, the anticipated result or outcome will not occur 
(Bartholomew et ah, 2001). Important outcomes or indicators of the proposed evaluation 
framework for enhanced TB surveillance in First Nation children include evidence of routine 
screening for TB and appropriate follow-up and treatment for those affected in order to prevent 
transmission of TB within the community. 
4. Evaluation Design 
Evaluations should be carefully designed in order to strengthen project activities and address 
important evaluation questions (W.K. Kellogg Foundation, 1998), though these may change over 
the course of the program. To account for possible changes in evaluation needs, the evaluation 
framework must be flexible. Flexibility of the evaluation design can be achieved by: 1) designing 
an evaluation that “fits” the needs of the target audience and stakeholders, 2) gathering only the 
data relevant to the specific questions, 3) revising the evaluation questions, plans, and data 
collection as project conditions change, 4) being sensitive to the cultural issues and history of 
communities, 5) knowing what resources are available for evaluation, 6) understanding existing 
capacity for staff to assist, and 7) being aware of the limitations of existing technologies and 
allowing for time interruptions (W.K. Kellogg Foundation, 1998). 
Combining process and outcome evaluations can be a valuable way to assess efficiency of the 
program, as well as whether or not it achieved the desired effect (CDC TB Program Evaluation 
Handbook, 2006). While process evaluation measures the extent to which the intervention was 
delivered as intended, outcome evaluation seeks to assess the short term changes in perceptions, 
attitudes or other factors that have led to a change in behaviour or health status (Glanz, Rimer & 
Viswanath, 2008). With respect to the evaluation of the effect of the enhanced TB surveillance 
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screening of First Nation children, the change in rates of TB (the health problem) should be 
examined, as should the factors that contributed to the change observed (Bartholomew et ah, 
2001). For the purpose of enhanced TB surveillance screening, the evaluation method should 
include both a process and outcome focus. 
According to evaluation research by W.K. Kellogg Foundation (1998) evaluation designs should 
always integrate both qualitative and quantitative data collection methods whenever possible in 
order to capture the richness and eomplexity of a program (W.K. Kellogg Foundation, 1998). For 
this reason, it is essential that the enhanced TB screening program incorporate both quantitative 
and qualitative data. 
The WHO also highlights the importance of strengthening routine recording and reporting 
systems, as well as the importance of surveillance of all cases to improve estimates of burden 
and trends in a given population (WHO, 2008). For the purpose of enhanced surveillance in First 
Nation populations, data concerning TB surveys or screening is collected by community health 
nurses working within the community. Reporting TB cases to the local TB program is an 
essential public health function, and in most cases is legally mandated (International Standards 
for Tuberculosis Care, 2006). All reporting systems should be designed and eapable of receiving 
and integrating data from several sources such as laboratories, hospital and individual 
practitioners (International Standards for Tuberculosis Care, 2006). Hence, the routine data 
collection processes between First Nation communities and the TB program should be 
standardized and concise. 
In terms of assessing the impact of TB control efforts in First Nation populations, surveys and in- 
depth analysis of routine surveillance data should be used to both measure impact and establish a 
baseline in the community (WHO, 2008). One method to monitoring population based TB 
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control efforts can be done by calculating the incidence, which represents the number of new 
cases of TB that occur each year (WHO, 2008). As was mentioned earlier, the long term goal is 
to reduce the incidence of TB to 3.6 per 100,000 populations by the year 2015, and in doing so 
an indicator has been established to reach an annual reduction of 3.3% between 2007 and 2015. 
How this will occur depends on what the program objectives are to reach this milestone, which 
may include, for example, a specific number of community education sessions, people receiving 
LTBI treatment, or people completing treatment. 
Logic models and intervention mapping are useful in public health for development of health 
promotion and prevention programs, and they provide planners with a framework for effective 
decision making at each step of the planning, implementation, and evaluation process 
(Bartholomew et al., 2001). The focus of the evaluation design can best be understood through 
the use of logic models, as they make it easier to identify the pertinent questions to be addressed 
(CDC TB Program Evaluation Handbook, 2006).The logic model for the enhanced TB 
surveillance screening program is illustrated below (Figure 1). 
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Figure 1: Enhanced Surveillance Screening Evaluation Map 
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I 
Source: CDC TB Evaluation Handbook, 2006; Intervention Mapping, Bartholomew et al., 2001 
Throughout the process, it is important to return to the evaluation questions regularly; evaluation 
teams often lose focus and end up concentrating too much on the information and methods to 
collect information. Therefore the more closely you design your evaluation to the priority 
questions, the more effective the team will be in finding the answers (W.K. Kellogg Foundation, 
1998). 
5. Data Collection 
Decisions on which questions to address and what information is required to answer those 
questions should be identified early in the planning process to minimize the risk of collecting 
irrelevant data, and to ensure that needed data is available (W.K. Kellogg Foundation, 1998). 
There will be numerous methods to choose from for data collection. Of importance to any 
evaluation is the extent of the validity and reliability of the data sources and instruments, which 
can increase or decrease credibility of the evaluation (CDC TB Program Evaluation Handbook, 
2006). Most TB programs routinely collect massive amounts of data that will provide the 
required information for most outcome indicators (CDC TB Program Evaluation Handbook, 
2006). Evaluating the timeliness of public health surveillance systems helps to determine 
availability of data for the health related event, intervals from the onset of symptoms or date of 
exposure to reporting the event and treatment, immediate control and prevention interventions, 
and overall program planning (CDC Updated Guidelines for Evaluating Public Health 
Surveillance Systems, 2001). 
Data collection methods will vary according to the design and evaluation questions; for outcome 
evaluations, the use of surveillance and monitoring data is essential, whereas quantitative and 
qualitative data are used in process evaluation (Glanz et ah, 2008). The Indigenous Stop TB 
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Strategy was implemented in 2008 to increase both awareness and surveillance of the burden of 
TB globally in an Indigenous context; this strategy represents an extension of the existing Stop 
TB Strategy that enhances National TB programs in various countries (A Global Indigenous 
People’s Initiative to Stop TB, 2009). An important component of the Stop TB Strategy is a 
toolkit that provides guidance and a minimum set of indicators related to the quality of 
performance at service delivery levels (WHO, 2008). Select impact/outcome indicators for the 
enhanced TB screening program that can be used within the proposed program evaluation 
framework are outlined in Table 5. Note that the focus is on quantitative measures. 
Table 5. World Health Organization Indicators for Tuberculosis Programs 
Indicator Target Measurement 
Impact 1. TB Incidence Rate: 
Estimated number of TB cases (all 








The notification rate can be a close proxy of 
TB incidence where the coverage and quality 
of the routine surveillance system is high; the 
trend in TB incidence can be measured by 
assessment of trend in case notifications if 
there have not been significant change in case 
finding efforts and/or recording and reporting 
practices.  
2. TB Prevalence Rate: 
Estimated number of TB cases (all 
forms) per 100,000 populations at 
a given point in time. 





Measured by population-based disease 
prevalence survey where applicable 
3. TB Mortality Rate: Estimated 
number of deaths due to TB (all 




rates by 2015, 
relative to 
1990 rates. 
Measured by high quality and coverage vital 
registration system or population based 
mortality survey. 
Outcome 1. Case Detection Rate: 
New smear positive TB patients 
detected and reported to the 
national health authority, among 
the new smear positive TB patients 
estimated to occur countrywide 
each year (number and percentage) 




Measured by routine recording and reporting 
system. 
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2. Treatment Success Rate: New 
smear positive TB patients cured 
plus completed treatment among 
the new smear positive TB patients 
registered during a specified period 
(number and percentage). 
At least 85% 
successfully 
treated 
Measured by routine recording and reporting 
system. 
Source: WHO Monitoring and Evaluation Toolkit: HIV, TB and Malaria, Draft 2008, page 17. 
Qualitative data is information that can be used to describe how the program is functioning and 
deals with the context of the program or people’s experiences and the meaning they attach to that 
experience (W.K. Kellogg Foundation, 1998). This type of information may be obtained through 
interviews with stakeholders, focus groups, observation, or case studies (CDC TB Program 
Evaluation Handbook, 2006). Qualitative data can be collected by posing questions to better 
understand the impact of TB in First Nation communities. The use of open-ended question data 
tools to focus on distinct perspectives in order to understand and contrast is important (W.K. 
Kellogg Foundation, 2007). For example; how has the impact of TB affected your community? 
Explain how TB has impacted on your family or children? What does TB prevention mean to 
you? What are some of the positive or negative experiences you have encountered with the TB 
program? Identifying various perspectives will help uncover new information and 
understandings to shape the next phase of the program, which may be significantly enhanced by 
new opportunities (W.K. Kellogg Foundation, 2007). 
6. Data Analysis and Interpretation 
Analysis of data involves looking at what the data represents and what it insinuates when 
compared with benchmarks or standards (CDC TB Program Evaluation Handbook, 2006). If the 
program data fails to produce the desired outcome, then process evaluation data can be helpful in 
determining why the program failed, and what program modifications may be needed 
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(Bartholomew et ah, 2001). One of the performance indicators that have been set out for the 
BCCDC TBS AC program has been to reduce the TB incidence to 3.6 per 100,000 people by 
2015 in all Aboriginal communities, in accordance with the long term national goal (Canadian 
Tuberculosis Standards, 2007). The incidence of TB is the number of new cases of TB that occur 
each year and can be measured by six methods: 1) directly from TB notification data; 2) directly 
from prospective cohort studies; 3) indirect estimation based on surveys of annual risk of 
infection (ARI); 4) indirect estimation from studies of the prevalence of TB in the population; 5) 
indirectly from vital registration data including TB mortality data; 6) indirect estimation from 
assessment of the complete TB notification data (WHO, 2008). 
All cases of TB are captured on the public health information system kept by BCCDC as 
previously mentioned. Quantitative data analysis will require interpretation of the results by a 
statistician and software program designed to capture aggregate data (WHO, 2008). When using 
inferential statisties, the first step is to create subgroups within the population and examine your 
sample to ensure you have an appropriate size, in addition to critieal variables of gender or age 
(National Library of Medicine, 2006). For example, the evaluation of surveillance screening 
activity of First Nation children will need to include age, gender, time period for TB screening 
and TST results. Statistical tests such as chi square and t-test can be used to test the significance 
of relationships between variables (National Library of Medicine, 2006). Table 6 is an example 
of TST results by time period for First Nation ehildren (n=1677) during BCG and after 
diseontinuation of BCG using frequency and percent. 
Table 6. Tubercu in Skin Test Resul s for First Nation Children 




























Source: BCCDC TB Control Program, Epidemiology Report, 2009. 
An analysis summary of this table can best be explained by asking the following question: How 
many First Nation children tested positive with a TST during the time periods specified? The 
generalization we can conclude is that 1.72% of children who have not had a BCG had a positive 
TST, while 4.96% of First Nation children who had received BCG had a positive test result. We 
may also draw a conclusion that some of these children who had a BCG vaccination tested 
positive on the TST because of BCG vaccination interference with the TST; therefore these 
results may indicate false positives. Table 7 is an example of a statistical table of results 
generated using a Statistical Analysis System 9.1.3. (SAS) for First Nation children during BCG 
and after discontinuation of BCG. 
Table 7. Demographic Characteristics of Aboriginal Children in British Columbia, TB 
Control 1998 - 2005 (n=1677)  


































Source: BC Center for Disease Control, Epidemiology Report, 2009. 
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This table represents all First Nation children (n=1677) categorized by gender, age, TST results 
and TB cases spanning a seven year period. Analysis yields that more children were screened 
prior to discontinuation of BCG in 2003; however the post BCG results may appear low since 
screening is on an annual basis, hence only 2 screenings were done during that time. The 0-4 
year age groups screened are relatively consistent and will vary depending on birth rates. The 
higher number of positive TST results in the BCG vaccinated population is expected due to some 
interference of the BCG vaccine. There were fewer active TB cases even after discontinuation of 
BCG, which would support the evidence that BCG does not prevent TB infection. A total of 9 
TB cases were detected in children for this period, and all have received treatment. 
7. Dissemination of Results 
All participants and stakeholders involved in the evaluation process should receive a written 
formal report that summarizes conclusions and recommendations from the evaluation, including 
action steps to improve the program (CDC TB Program Evaluation Handbook, 2006). Not only 
will dissemination of evaluation results help improve programs, but they also contribute to the 
development of new knowledge for others to utilize. The creation of new theory refines existing 
theories and contributes to further evidence based practice for interventions (Glanz et al., 2008). 
It is generally agreed upon in public health practice that any impact will occur when effective 
interventions are disseminated widely and as often as possible (Glanz et al. 2008). All too often, 
many evaluation reports make the mistake of simply documenting project activities and 
expenditures and convey little about lessons learned and significant outcomes (W.K. Kellogg 
Foundation, 1998). Effective evaluations support action and should inform decisions, clarify 
options, identify strengths and weaknesses of a program, and provide recommendations for 
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improvements; therefore during each planning and implementation step stakeholders and 
evaluators need to be engaged about how results will be used to make decisions (W.K. Kellogg 
Foundation, 1998). 
Dissemination of evaluation results to First Nation communities affected by TB is essential, but 
commitment to sustainability of TB control efforts and transfer of public health knowledge to the 
grass roots level is fundamental for communities to take control and ownership over TB. The 
Canadian Institute of Health Research (CIHR) in collaboration with its’ Aboriginal Health 
division has helped move population and public health knowledge into action for some of these 
communities through research initiatives aimed at successful knowledge translation (CIHR, 
2006). Previously, public health care utilization data had only the attention of researchers and 
academia, but the shift is now towards empowering and partnering with First Nation 
communities to build research capacity and establish successful research opportunities to build 
an evidence base for policy claims (Elias & O’Neil, 2006; CIHR, 2006). In terms of TB control 
at the community level, there may also be the opportunity to uncover other important prevention 
factors outside of the traditional case detection and treatment protocol that currently exists for 
TB control strategies. 
8. Implementation of Evaluation 
The implementation of evaluation will depend on the phase of the project, the purpose of the 
evaluation and particular questions you are attempting to address (W.K. Kellogg Foundation, 
1998). In this case, the enhanced surveillance screening of First Nation children in BC is a 
program that has been operating for several years already. When evaluating an established 
program, the evaluation may be designed as a continuous monitoring, feedback, and 
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improvement loop that will provide staff with ongoing feedback for modification or reform 
(W.K. Kellogg Foundation, 1998). A population based screening framework was developed in 
Australia in 2008, and may be useful for implementation and management of TB screening 
programs elsewhere (Australian Population Based Screening Framework, 2008). The screening 
framework’s key principles for monitoring and evaluation include: 1) developing a formal 
approach for on-going monitoring and evaluation; 2) identify appropriate measurable indicators; 
3) develop indicators that enable comparison over years and between international programs; 4) 
develop nationally consistent methods for reporting and collecting data under indicators; 5) 
identify reporting milestones; 6) align evaluation with quality management plan; and 7) identify 
timeframes that necessitate program review (Australian Population Based Screening Framework, 
2008). 
9. The Cost ofTB 
The actual expenditures of TB care in Canada prior to an analysis done in 2006 by Menzies and 
colleagues were virtually unknown due to the complexity of various federal, provincial, 
territorial, county and municipal governments involved in diverse aspects of TB care. Total 
government expenditures for TB in 2004 was calculated to be $47,290 per active TB case, 
equivalent to $74 million, while actual expenditures attributed to patient care with active TB 
totaled $19,906 per case, or a total of $31 million. Those patients being treated for latent TB 
infection cost $845 per patient on therapy, for a total LTBI expenditure of $10.1 million. Contact 
tracing expenditures were $8.3 million or an average of $300 per contact screened and research 
was designated $4.5 million. These calculations do not include expenditures for the Aboriginal 
TB program that is funded by FNIH; the federal government budget for on-reserve TB care in 
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each province. TB in Canada, particularly active TB cases cost considerably more than 
prevention and treatment of latent TB infection, however, Canada’s expenditure is comparable to 
other high-income countries. Almost half of these expenditures for active TB cases are made for 
hospitalizations, laboratory costs and public health staffing. Provinces and territories have been 
spending close to double ($52.5 million) of what the federal government contributed ($16.3 
million) for TB related care (Menzies, Oxlade & Lewis, 2006). In these uncertain economic 
times, the enhancement of uptake for screening and treatment of LTBI would be prudent. The 
federal government contribution of $16.3 million is used for overseas and in-Canada screening 
for active TB among immigrants and refugees, TB control in federal correctional institutions, 
PHAC TB Prevention and Control Program, National Reference Centre for Mycobacteriology, 
and Aboriginal TB care (Menzies et al., 2006). Supplement of TB funding and partnerships from 
provincial TB programs are crucial to the existence of Aboriginal TB programs. An example; in 
2007 there were 307 cases of active TB in the Aboriginal population for Canada (PHAC, 2007a), 
and if we use the formula from Menzies et al., 2006 cost analysis, the total cost of TB care is 
$14.5 million, not including resources required for LTBI treatment or screening activities. This 
expenditure alone would take up the majority of the federal government contribution. Active TB 
cases are preventable, and the repercussions for public health and Canada in general will 
continue to be costly if quality TB treatment and prevention, surveillance and advocacy for 
social change are not delivered to those who need it most. 
10. Implications for Public Health Practice and Policy 
Evaluation of enhanced surveillance screening of First Nation children in the province of BC will 
undoubtedly reveal findings that will directly or indirectly impact on current TB control 
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practices. The majority of evidence indicates that screening children in high risk TB areas is an 
important indicator of public health achievement in disrupting and preventing the transmission of 
TB. However, to do so requires the necessary resources and expertise of TB control providers. 
For example, Lobato and associates (2000) have reported that important missed opportunities to 
prevent TB in children in the US are largely due to public health case mismanagement. The 
importance of contact investigation, screening guidelines, resources, HIV and substance use, 
social determinants of health. 
10.1 Contact Investigation 
It is well established that positive TST results in children represent TB transmission from an 
adult source case, and that contact investigation of the source case is the only means to identify, 
treat and prevent further TB cases. A study by Lobato, Mohle-Boetani, and Royce (2000) 
examined data records for 165 children with active TB and found that only 37% of children had 
a source case identified, and 7% had no record of any contact investigation. There were also 
numerous children who were not properly evaluated - they received no TB evaluation at all, 
there were delays in reporting source cases, no chest radiograph were performed, and treatment 
was not started in a timely manner (Lobato et ah, 2000). The authors further concluded that at 
least 11% of these cases may have been preventable. Based on these findings it appears that 
either resources are not adequate to carry out contact investigations, or communication, 
education and timely interventions within the TB program are deficient. Regardless, findings 
point to missed opportunities for TB prevention. 
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10.2 Screening Guidelines 
Heymann and colleagues (2000) have provided evidence of need for public health policy to both 
improve and maintain stringent TB screening guidelines for First Nations. They found that TB 
control programs have been less successful among children than in adults, which points to the 
need for multiple interventions aimed at improving screening of children and adults in high-risk 
First Nation communities. 
10.3 Resources 
Determination of what resources are needed to appropriately and adequately manage TB 
interventions at differing Aboriginal community levels and locations is an important 
consideration for public health practitioners and decision-makers. Ideally, the enhanced TB 
surveillance and screening of First Nation children would occur in an established community that 
has a school willing to participate and where there is adequate public health staffing; however it 
is not always a realistic one given both the changing epidemiology of TB and limited resources 
in some communities. In addition, there is a large proportion of the First Nations population that 
resides in urban areas and account for an increasing number of TB cases in those regions. In fact, 
in some urban areas of Canada, the incidence of TB among urban Aboriginal people is equal to 
or higher than the ineidence among those living on-reserve (Canadian Tuberculosis Standards, 
2007). Just over half (53%) of registered First Nation individuals live on one of Canada’s 2,796 
reserves, and the remainder live off-reserve (Canadian Tuberculosis Standards, 2007). For this 
reason, it is important that enhanced TB surveillance programs targeting First Nations children 
also happen in urban areas, off-reserve. 
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10,4 HIV and Substance Use 
Public health practices and policies will also need to be mindful of increasing rates of HIV, 
substance abuse and injection drug use - all of which have a direct impact on TB control 
measures. A recent study by Callaghan and colleagues (2007) provided a retrospective medical 
chart review of inpatient detoxification records that illustrated the mobility patterns of Aboriginal 
injection drug users (IDU) between on and off reserve communities. The reciprocal movement 
between these settings is contributing substantially to the transmission of HIV and other 
infectious diseases. During the period 1998-2003, there were 59.4% of HIV positive cases 
attributed to IDU in the Aboriginal population. It is often assumed that IDU is largely confined 
to urban centers; however, it affects all settings. It is well known that HIV and TB co-infection 
is the greatest contributer to mortality (Callaghan, Tavares, & Taylor, 2007). In 2000, a Health 
Canada report concluded that substance abuse was a risk factor in 47.6% of all TB cases for BC 
and Alberta on-reserve populations (Health Canada, Tuberculosis in First Nation Communities 
1990-2000). As a result, publie health practice will need to address the challenge of substance 
abuse behavior and work in partnership with communities to reduce this associated risk for TB. 
10.5 Social Determinants of Health 
Substantial resources are required to align current TB practices and socioeconomic strategies if 
TB is ever to be eliminated in the Aboriginal community. Progress towards economic 
sustainability and improvements in the social determinants of health in most Aboriginal 
communities has been dismal and shameful in Canada. Data from the 2005 Statistics Canada 
report reveals that in urban centers such as Toronto, 27% of Aboriginal people lived under the 
low-income cut-off compared to 18% for non-Aboriginal populations. Further, though 
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Aboriginal people made up approximately 2.7% of Canada's population in 2001, it consisted of 
about 2.5% of the labour force (Statistics Canada, 2007). These reports indicate that poverty in 
Aboriginal populations and communities remains a pressing issue that negates TB control 
efforts. Schluger (2005) reiterates this reality by stating that “the antituberculosis movement 
cannot be understood if seen only in its medical perspective, for the historical and social 
backgrounds looms large in the picture” (Schluger, 2005, p.245). This remains the principle 
challenge for public health TB control programs. 
11. Summary 
TB continues to be one of the most challenging infectious diseases, and has yet to be eradicated. 
In Canada, TB affects a significantly higher number of First Nations people, and so efforts to 
prevent, manage, and treat TB must be culturally appropriate to ensure buy-in from First Nations 
communities. The changing epidemiology of TB has implications for public health planning and 
prevention initiatives as chronic illness, HIV, and daunting socioeconomic trends continue to 
plague First Nations communities. 
TB Control programs build upon a specialized body of knowledge that has been evolving for 
many years, and while technology has paved the way for enhanced surveillance activities that 
capture the ever changing patterns of disease within populations, it cannot solve the problem 
itself, or the numerous social underpinnings that contribute to it. 
The evaluation of enhanced screening and surveillance of First Nation communities, particularly 
children, is an important component of TB Control programs. The research and evidence that 
support the process of enhanced TB surveillance has been a developmental work in progress 
from the early days of TB control. The TB control strategies used today are predominately based 
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on the rich experiences of others, trials and errors, and most prominently, the outcomes of prior 
evaluations. The evaluation framework suggested here is meant to guide and support TB 
program development. Evaluation of the enhanced surveillance screening efforts of TB control 
will undoubtedly yield more questions than answers, and more challenges than solutions, but it 
remains a noble pursuit as it strives to improve the health of First Nations communities. The 
health and well-being of Aboriginal people is fundamental for the health and wealth of Canada 
as a whole, and any investment into the health of this subset of the population will yield return 
for all Canadians. 
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BCG Policies and Practices in Select Countries 
Sweden 
TB prevalence is currently 5 per 100,000 population and historically recommended BCG for everyone. 
BCG was first introduced in the 1940s. Current practice is to vaccinate only select high risk groups such 
as children at increased risk for exposure to TB and immigrants born in high incidence areas. 
United States 
TB prevalence is 3 per 100,000 population and has never recommended BCG for everyone in this 
country. BCG was only given to high risk groups such as health care workers. 
Germany 
TB prevalence is 5 per 100,000 population and used to recommend BCG vaccination for everyone, but 
currently does not. Vaccination was introduced in 1961 and given at birth. It was discontinued in 1998 as 
a routine, and is now given only to high risk children. 
Spain 
TB prevalence is 24 per 100,000 population. This country used to recommend BCG vaccination for 
everyone, but currently only gives to high risk groups. 
United Kingdom 
TB prevalence is 12 per 100,000 population. This country used to recommend BCG vaccination for 
everyone, but currently does not. BCG was introduced in 1953 and discontinued in 2005. BCG was 
previously given to adolescents, now only infants at risk for TB and health care workers get BCG 
vaccination. 
Canada 
TB prevalence is 4 per 100,000 population. BCG was never recommended for everyone in this country, 
and was given to only high risk groups including children, health care workers and First Nations. 
Source: World Atlas of BCG Policies and Practices (2009) http://w ww.bcgatlas.org/ 
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Appendix 2 
Methodology for Literature Search 
A search for literature was undertaken using the PubMed MeSH database, Cochrane Library and Google 
search for appropriate articles relating to Tuberculosis, BCG vaccination. Aboriginal populations and 
evaluation methods. The search focused on current literature between 1998-2008. 
MeSH terms used: 
BCG vaccine AND Aboriginal children (0) hits for Aboriginal or First Nations 
BCG vaccine (15157) 
BCG vaccine AND Children (3167) 
BCG vaccine AND Population Groups (129) 
BCG vaccine AND Population Surveillance Programs AND Tuberculosis (89) 
Tuberculosis vaccines AND Outcome Process Assessment (3003) 
Tuberculosis AND Health Care Evaluation Mechanisms (23566) 
Tuberculosis AND Health Care Evaluation Mechanisms AND Mass Screening (2475) 
Google terms used: 
Tuberculosis AND Canada 
Tuberculosis AND Aboriginals 
Tuberculosis AND First Nations 
Cochrane Library terms used: 
Tuberculosis (5933) 
BCG Vaccine (27436) 
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Appendix 3 
International Standards of Tuberculosis Care 
Standards of practice for the care of those afflicted by TB are consistent with World Health Organization 
(WHO) recommendations, and are intended to support and guide health care praetitioners in diagnosis, 
treatment and public health policy (International Standards for TB Care, 2006). 
Standards for Diagnosis 
1. A productive cough lasting two-three weeks or more should be evaluated for TB 
2. All patients suspected of having pulmonary TB should have at least two, and preferably three sputum 
specimens obtained. When possible, at least one specimen in the early morning should be obtained. 
3. All patients suspected of having extrapulmonary TB should have appropriate specimens obtained 
from suspected sites for microscopy. 
4. All persons with chest radiographic findings suggestive of TB should have sputum specimens 
submitted for microbiology examination. 
5. Diagnosis of sputum smear-negative TB should be based on these criteria: at least three negative 
sputum smears; chest x-ray findings consistent with TB; and lack of response to a trial of broad 
spectrum antimicrobial agents. In persons with known HIV infection, the diagnostic evaluation 
should be expedited. 
6. The diagnosis of intrathoracic TB in symptomatic children with negative sputum smears should be 
based on the finding of chest x-ray abnormalities consistent with TB, and either a history of exposure 
to an infectious case or evidence of TB infection. 
Standards for Treatment 
1. Any practitioner treating a patient with TB is responsible to prescribe an appropriate regimen and 
capable of assessing adherence of the patient to the regimen. Including addressing poor adherence 
when it occurs. 
2. All patients who have not been previously treated should receive an internationally accepted first-line 
treatment regimen using drugs of known bioavailability. Initial phase of two months isoniazid, 
rifampin, pyrazinamide, and ethambutol. Continuation phase for four months of isoniazid and 
rifampin. Alternative continuation can consist of isoniazid and ethambutol for six months when 
adherence cannot be assessed. Doses of antituberculosis drugs should conform to international 
recommendations based on combinations and directly observed therapy (DOT). 
3. A patient centered approach to administration of drug treatment based on patient’s needs and mutual 
respect should be developed. Supervision and support should be gender-sensitive, age specific and 
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should draw on supportive interventions and services, including education and counseling. This may 
include DOT. 
4. All patients should be monitored for response to therapy by follow-up with sputum microscopy at the 
time of completion of initial phase and completion of treatment. Patients who have positive smears 
during the fifth month of treatment should be considered as treatment failures and have therapy 
modified. 
5. Written records of all medications, bacteriology results and adverse reactions should be maintained 
for all patients. 
6. High prevalence areas of HIV infection and where TB and HIV infection are likely to co-exist should 
HIV test and counsel patients. 
7. All patients with TB and HIV eo-infection should be evaluated to determine if antiretroviral therapy 
is indicated during the course of treatment for TB. Consultation with a physician who is expert in this 
area is recommended before initiation of treatment. 
8. An assessment for drug-resistance, based on history of prior treatment, exposure to a drug-resistant 
organism, and the community prevalence of drug resistance should be obtained for all patients. 
9. Patients with drug-resistant (MDR) TB should be treated with specialized regimens containing 
second-line antituberculous drugs. A minimum of four drugs to which the organism is susceptible 
should be used, and treatment given for at least 18 months. 
Standards for Public Health Responsibilities 
1. All providers of care for patients with TB should ensure those children under 5 years and those with 
HIV infection who have been in close contact with an infectious case are screened, evaluated and 
managed. 
2. All providers must report new and re-treatment TB cases and treatment outcomes to local public 
health authorities. 
Source: Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care: 
Diagnosis, Treatment and Public Health. The Hague: Tuberculosis Coalition for Technical Assistance, 
2006. 
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